• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

CDC treats first mon­key­pox pa­tient with SIGA's small­pox an­tivi­ral via ex­pand­ed ac­cess

3 years ago
Pharma

Jazz Phar­ma­ceu­ti­cals taps celebri­ty ac­tor and epilep­sy ad­vo­cate to host YouTube ‘Care Giv­er’ se­ries

3 years ago
Pharma
Marketing

State supreme court rules in fa­vor of Eli Lil­ly in case over warn­ing pa­tients of risks when DTC ads are in play

3 years ago
Pharma
Law

FDA re­view spot­lights risk of heart in­flam­ma­tion linked to No­vavax's Covid vac­cine — shares tum­ble

3 years ago
FDA+
Coronavirus

#AS­CO22: Im­bru­vi­ca keeps ag­gres­sive blood can­cer at bay for 6+ years, but miss­es the mark in over­all sur­vival

3 years ago
R&D
Pharma

Bioethi­cists weigh in: Xeno­trans­plan­ta­tion may be here ‘with­in the next five years,’ but con­cerns loom

3 years ago
R&D

Im­mu­nic shares cut in half as biotech dumps ul­cer­a­tive col­i­tis af­ter PhII fail

3 years ago
R&D

Boehringer In­gel­heim inks deal for tar­get­ed can­cer an­ti­bod­ies from Sin­ga­pore re­search org

3 years ago
Deals
R&D

De­spite a PhI­II fail, Bio­gen push­es ALS drug tofersen for­ward with new analy­sis in move echo­ing Aduhelm

3 years ago
R&D

Amy­lyx's ALS drug gets a three-month PDU­FA de­lay, set­ting up the piv­otal de­ci­sion for Sep­tem­ber

3 years ago
R&D
FDA+

Bris­tol My­ers jumps in­to the M&A game with a $4B on­col­o­gy buy­out. And weary biotech an­a­lysts could­n't be any hap­pi­er

3 years ago
Deals

Days af­ter dis­clos­ing tri­al flop, stem cell ther­a­py de­vel­op­er ax­es 70% of work­force while search­ing for cash

3 years ago
People

All in on ear­ly-stage, Qim­ing US bags $260M, re­cruits Atara founder Isaac Ciechanover for Fund III

3 years ago
Financing

Time Pas­sages: Bruce Gold­smith out at Jim Wilson's gene ther­a­py biotech; Flag­ship re­veals Michael Sev­eri­no’s CEO ...

3 years ago
Peer Review

Re­gen­eron inks $1B+ deal for glob­al rights to Sanofi-part­nered PD-1 Lib­tayo

3 years ago
Deals
Pharma

Pfiz­er, like Mod­er­na, fires back at Al­ny­lam suit over Covid-19 vac­cine patents

3 years ago
Pharma
Coronavirus

No­var­tis re­sumes re­mote busi­ness in Ukraine af­ter safe­ty pro­to­col re­view

3 years ago
Pharma

An­oth­er refuse-to-file for a small biotech — is the FDA us­ing RTFs to man­age its work­load?

3 years ago
FDA+

Organon de­buts mu­rals cre­at­ed by women around the world, plus am­bi­tious ESG plan, on first an­niver­sary

3 years ago
Pharma
Marketing

Gilead poach­es new phar­ma de­vel­op­ment and man­u­fac­tur­ing chief from cell ther­a­py 2.0 play­er

3 years ago
R&D
Manufacturing

FDA com­pli­ance vet heads to In­dia-based Lupin af­ter long pub­lic ca­reer

3 years ago
People
FDA+

Man­u­fac­tur­ing roundup: Lon­za col­lab­o­rates with a VC in Is­rael; Pi­ra­mal up­dates one fa­cil­i­ty while open­ing a new one

3 years ago
Manufacturing

The tar­get is the sys­tem: Con­den­sates biotech as­pires to ‘rewrite the rule­book’ on drug dis­cov­ery

3 years ago
Financing

Bio­gen, Sam­sung Bioepis look to carve up a block­buster Roche fran­chise with deep dis­count biosim­i­lar

3 years ago
Marketing
First page Previous page 511512513514515516517 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times